RA CAPITAL MANAGEMENT, L.P. - 26 Sep 2025 SCHEDULE 13D Report for SAB Biotherapeutics, Inc. Common Stock, $0.0001 par value per share (SABS)

Filing Manager: RA CAPITAL MANAGEMENT, L.P.
Reporting Manager: RA Capital Management, L.P.
Security: SAB Biotherapeutics, Inc. Common Stock, $0.0001 par value per share
Symbol: SABS
Shares outstanding: 44,459,596 shares
Disclosed Ownership: 4,401,500 shares
Ownership: 9.9%
Form type: SCHEDULE 13D
Filing time: 03 Oct 2025, 16:26:17 UTC
Date of event: 26 Sep 2025
Next filing: 11 Mar 2026
SEC: View on sec.gov

Quoteable Key Fact

"RA CAPITAL MANAGEMENT, L.P. disclosed 9.9% ownership in SAB Biotherapeutics, Inc. Common Stock, $0.0001 par value per share (SABS) on 26 Sep 2025."

Quick Takeaways

RA CAPITAL MANAGEMENT, L.P. filed SCHEDULE 13D for SAB Biotherapeutics, Inc. Common Stock, $0.0001 par value per share (SABS).
Disclosed ownership: 9.9%.
Date of event: 26 Sep 2025.

This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
You can verify ownership claims directly against the original SEC filing.

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

Name	Ownership	Shares Owned	shared voting power	Signature	Title	CIK
RA Capital Management, L.P.	9.9%	4,401,500	4,401,500	/s/ Peter Kolchinsky	By Peter Kolchinsky, Authorized Signatory	0001346824
Peter Kolchinsky	9.9%	4,401,500	4,401,500	/s/ Peter Kolchinsky	Peter Kolchinsky	0001384859
Rajeev Shah	9.9%	4,401,500	4,401,500	/s/ Rajeev Shah	Rajeev Shah	0001619841
RA Capital Healthcare Fund, L.P.	9.9%	4,401,500	4,401,500	/s/ Peter Kolchinsky	By RA Capital Healthcare Fund GP, LLC, its General Partner, By Peter Kolchinsky, Manager	0001315082